Relationships of Coronary Heart Disease With 27-Hydroxycholesterol, Low-Density Lipoprotein Cholesterol, and Menopausal Hormone Therapy | Zendy

Jacques E. Rossouw | Zendy; Ross L. Prentice | Zendy; JoAnn E. Manson | Zendy; Aaron K. Aragaki | Zendy; Judith Hsia | Zendy; Lisa W. Martin | Zendy; Lewis H. Kuller | Zendy; Karen Johnson | Zendy; Charles B. Eaton | Zendy; Rebecca D. Jackson | Zendy; Maurizio Trevisan | Zendy; Matthew Allison | Zendy; Ron C. Hoogeveen | Zendy

Open Access

Relationships of Coronary Heart Disease With 27-Hydroxycholesterol, Low-Density Lipoprotein Cholesterol, and Menopausal Hormone Therapy

Author(s) -

Jacques E. Rossouw,

Ross L. Prentice,

JoAnn E. Manson,

Aaron K. Aragaki,

Judith Hsia,

Lisa W. Martin,

Lewis H. Kuller,

Karen Johnson,

Charles B. Eaton,

Rebecca D. Jackson,

Maurizio Trevisan,

Matthew Allison,

Ron C. Hoogeveen

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.103218

Subject(s) - medicine , confidence interval , odds ratio , estrogen , hormone therapy , mediation , endocrinology , menopause , cardiology , cholesterol , law , cancer , breast cancer , political science

Menopausal hormone therapy (MHT) increases the risk of coronary heart disease (CHD) in older women with elevated low-density lipoprotein (LDLC) levels. The endogenous estrogen receptor antagonist 27-hydroxycholesterol (27OHC) is correlated with LDLC levels and may block the beneficial effects of estrogen on the cardiovascular system.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research